Redalpine

Redalpine
Name	Redalpine
Type	Private
Industry	Venture capital
Founded	2006
Headquarters	Zurich, Switzerland
Key people	Eugen Müller, Marcel Ospel, Daniel Gutenberg
Products	Early-stage investment, seed funding, Series A
Assets	Venture funds

Redalpine is a European venture capital firm focused on early-stage technology investments in life sciences, deep tech, digital health, and industrial technologies. Founded in 2006 and headquartered in Zurich, the firm operates across key innovation hubs in Europe and North America, partnering with founders and institutions to scale startups toward growth rounds and exits. Redalpine combines sector expertise, institutional networks, and operational support to accelerate portfolio companies from seed to Series A and beyond.

History

Redalpine was established in 2006 amid increased venture activity in Zurich and Geneva, building links with ETH Zurich, University of Zurich, EPFL, and incubators such as Massachusetts Institute of Technology spinout programs. Early partnerships and limited partners included family offices from Switzerland, research foundations tied to Max Planck Society and corporate investors from Siemens and Novartis. The firm expanded offices and presence to ecosystems including Berlin, London, Los Angeles, and New York City to source opportunities and support portfolio companies. Over successive funds, Redalpine refined a thesis emphasizing cross-border scaling, co-investments with firms like Accel Partners, Index Ventures, and Balderton Capital, and collaboration with corporate venture arms such as Google Ventures and Pfizer Ventures.

Services and Products

Redalpine provides seed and early-stage capital, board representation, and operational mentorship for founders. Its services include deal sourcing through partnerships with accelerators like Y Combinator, technology transfer offices at Harvard University and Imperial College London, and corporate scouts from ABB and Roche. The firm offers portfolio support in hiring via networks including LinkedIn and McKinsey & Company alumni, commercialization guidance drawing on contacts at Bayer and Johnson & Johnson, and introductions for strategic partnerships with platforms such as Amazon Web Services and Microsoft Azure. Redalpine also runs founder events and workshops in collaboration with ETH Zurich incubators and startup communities like Station F and Techstars.

Investment Strategy and Portfolio

Redalpine targets seed and Series A rounds in sectors including biotechnology, medtech, AI, robotics, and industrial software. The fund’s strategy emphasizes capital-efficient product-market fit, technical due diligence leveraging labs at CERN and Fraunhofer Society, and follow-on reserves to support scaling. Notable portfolio companies span therapeutics, diagnostics, and hardware: biotech startups aligned with research from Imperial College London and Karolinska Institutet, robotics firms connected to ETH Zurich and EPFL, and AI ventures drawing on collaborations with University College London and Oxford University. Co-investors in portfolio rounds have included Sequoia Capital, Benchmark Capital, General Catalyst, and Khosla Ventures.

Corporate Structure and Governance

Redalpine is structured as a private partnership with general partners responsible for investment decisions and limited partners providing capital commitments. Governance includes an investment committee drawing expertise from former executives at Novartis, Credit Suisse, UBS, and academics affiliated with ETH Zurich and EPFL. Compliance and audit functions liaise with professional firms such as PwC and Deloitte, while legal counsel coordinates with firms that have represented entities like Roche and Novartis. The firm maintains advisory boards comprised of entrepreneurs and scientists from institutions including Imperial College London, Max Planck Society, and Karolinska Institutet.

Funding and Financial Performance

Redalpine has raised multiple funds since its inception, with capital commitments from family offices, university endowments, and institutional investors across Europe and North America. Funds have been deployed into early-stage rounds with ticket sizes typical of seed and Series A investing, and the firm reserves capital for follow-on rounds. Performance metrics cite portfolio exits and follow-on valuations in rounds led by investors such as Accel Partners and Index Ventures. Limited partners include foundations and pension funds comparable to those investing alongside European Investment Fund mandates and pan-European venture allocations.

Notable Exits and Impact

Redalpine portfolio companies have achieved exits and strategic acquisitions by corporations including Roche, Thermo Fisher Scientific, Siemens Healthineers, and GE Healthcare. Some ventures went public on exchanges such as NASDAQ and SIX Swiss Exchange, while others were acquired by multinational corporations like Johnson & Johnson and Medtronic. The firm’s investments contributed to commercialization of technologies originating from ETH Zurich and EPFL, and spurred regional startup ecosystems in Zurich, Geneva, and Berlin, supporting job creation and technology transfer from research institutions to industry.

Controversies and Legal Issues

Like many venture firms, Redalpine has faced scrutiny over portfolio company valuations, governance disputes at investee firms, and alignment between limited partners and founders during down rounds. Some investee restructurings involved litigation or arbitration reminiscent of disputes seen in cases involving firms such as Theranos and corporate litigation involving Groupon-era governance questions. Redalpine has engaged external counsel from law firms experienced with disputes involving Roche and Novartis-sized litigations to resolve contractual and governance issues, and implemented revised term sheet practices to clarify founder protections and investor rights.

Category:Venture capital firms